Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that it has closed the acquisition ...

The transaction, finalized following regulatory clearance, includes two FDA-approved rare tumor therapies: Ogsiveo for ...

Shares of SpringWorks Therapeutics SWTX have rallied 32.9% in the past three months compared with the industry’s increase of 2.7%. Here, we discuss the reasons for the same. Strong Launch of ...

SpringWorks Therapeutics Inc. (NASDAQ:SWTX) is one of the best biotech stocks to invest in now. On June 20, SpringWorks Therapeutics announced that the European Medicine Agency’s Committee for ...

Shares of SpringWorks finished Monday up some 34% at their highest close since April 2022, handing back some earlier gains. Merck's German-listed shares ended the trading session down about 3%.

SpringWorks Therapeutics' drug for treating adult patients with a type of rare non-cancerous soft-tissue tumor will be sold in the U.S. at a list price of $29,000 for a 30-day supply, the company ...

Contacts. BeiGene Contacts: Investors Kevin Mannix +1 857-302-5189 [email protected] Media Kathleen Cuca +1 551-222-6790 [email protected] SpringWorks Contacts: Kim Diamond Vice President ...

SpringWorks Therapeutics, Inc. , the Stamford, Conn.,-based biotech that launched its initial public offering ("IPO") in September 2019, raising ~$186 via the issuance of 10.35m shares priced at ...

SpringWorks Therapeutics lost $5.15 a share on just over $5 million in revenue in FY2023. The current analysis consensus has losses dropping to $3.32 a share in FY2024 as sales soar to $192 million.